List of Elcys drug patents
Elcys is owned by Exela Pharma.
Elcys contains Cysteine Hydrochloride.
Elcys has a total of 10 drug patents out of which 0 drug patents have expired.
Elcys was authorised for market use on 16 April, 2019.
Elcys is available in solution;intravenous dosage forms.
Elcys can be used as method of using l-cysteine in an admixture for treating patients needing parenteral nutrition.
The generics of Elcys are possible to be released after 15 January, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905714 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10918662 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10933089 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905713 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10912795 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US11510942 | EXELA PHARMA | NA |
Jan, 2039
(15 years from now) | |
| US11510941 | EXELA PHARMA | NA |
Jan, 2039
(15 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
ELCYS family patents
10
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic